Answers are grounded in this paper and cite their sources.
Purpose: This 3-year study examined the safety and efficacy of customized corneal collagen cross-linking (CuRV) for keratoconus in patients from Oman.Methods: Corneal collagen cross-linking was initiated by the application of 0.1% riboflavin.Targeted ultraviolet-A light was applied to the treatment area, and the energy levels were customized according to the topographic findings.Efficacy assessments were conducted preoperatively and postoperatively at 1, 6, 12, 24, and 36 months.Uncorrected distance visual acuity (UCVA), best corrected distance visual acuity (BCVA), maximum keratometry (Kmax), mean keratometry (Kmean), and corneal pachymetry were measured.Results: Most eyes (17/20 or 85% and 15/20 or 75%) improved or remained stable in UCVA or BCVA, respectively, between baseline and 36 months.Mean changes in Kmax from baseline were significant at 6-36 months, ranging from -1.4 to -2.1 D of flattening.Most (80%) eyes demonstrated ≥1 D of flattening at 36 months compared with baseline.At 36 months, mean pachymetry values showed corneal thinning at 6 and 24 months compared with baseline values (p < 0.05).In terms of safety, 15 and 25% of eyes showed small deteriorations of UCVA and BCVA, respectively.Conclusions: Overall, CuRV was safe and effective for long-term stabilization of keratoconus progression.Stable improvement in visual function and corneal flattening were observed over the 3-year follow-up period.
No takes yet. Share an insight, caveat, or question.
Saidi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: